TREATMENT OPTIONS

---

Tepezza® (teprotumumab-trbw) is the first and only FDA-approved treatment for Thyroid Eye Disease.

• IV infusion every 3 weeks
• 8 total infusions over ~6 months
• Weight-based dosing
• Administered by infusion-trained registered nurses

In addition to standard treatment, BioSight may offer access to clinical trials evaluating investigational therapies for TED or related conditions.

Participation in clinical research may be an option for patients who:

• Meet study eligibility criteria
• Have active or refractory disease
• Are interested in contributing to advances in TED treatment

Clinical trial participation is voluntary and does not replace standard medical care unless determined appropriate by the study protocol.